Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis For Up to 3 Years: An Open-Label Extension of Randomized Clinical Trials

By sjmartinez • November 28, 2024

Armstrong AW, Lebwohl M, Warren RB, Sofen H, Imafuku S, Ohtsuki M, Spelman L, Passeron T, Papp KA, Kisa RM, Vaile J, Berger V, Vritzali E, Hoyt K, Colombo MJ, Scotto J, Banerjee S, Strober B, Thaçi D, Blauvelt A. Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis For Up to 3 Years: An Open-Label Extension of Randomized Clinical Trials. JAMA Dermatol. 2024 Nov 27. doi: 10.1001/jamadermatol.2024.4688. Epub ahead of print. PMID: 39602111.

Tags: Dermatology, Olive View DoM, Publications

Adult Reactive Infectious Mucocutaneous Eruption (RIME) from Concurrent Adenovirus and Mycoplasma pneumoniae Infections

Li J, Noveir SD, Bouri N, Cheng K, Saini I. Adult Reactive Infectious Mucocutaneous Eruption (RIME) from Concurrent Adenovirus and Mycoplasma pneumoniae Infections. J Gen[...]

TREM-1 as a novel immunotherapeutic target to treat pancreatic ductal adenocarcinoma

Gross L, Mutisheva I, Hillen H, Robatel S, Wartenberg M, Ma F, Bäriswyl L, Lee DJ, Modlin RL, Z'graggen K, Schenk M. TREM-1 as a[...]

New-Onset Perianal Eroded Lesion in a Pediatric Patient

Yan MJ, Galamgam J, Shen A, Mo J, Hogeling M. New-Onset Perianal Eroded Lesion in a Pediatric Patient. Pediatr Dermatol. 2025 Sep 8. doi: 10.1111/pde.70037.[...]